COPD Therapeutics Market Analysis

Route of Administration Segment Analysis

Inhalation is the dominant segment and is poised to hold the share of 95.3% by 2035. The segment is dominated to the direct use of drugs in the lungs for rapid action and minimized systemic side effects. The NIH highlights that inhaled therapy is the key product driving COPD management as it reaches the site directly for rapid action. This method is essential for both daily maintenance therapy and for providing quick relief from acute symptoms, making it the gold standard for this respiratory disease.

Product Segment Analysis

Within the product segment, inhalers are dominating the segment and are expected to command a major share by 2035. The dominance is due to the effectiveness in enabling direct drug delivery to the lungs and results in the rapid onset of action and reduces systemic side effects. Devices such as DPIs and pMDIs are essential for managing a chronic condition that is used daily, long-term medication. As per the NLM study in July 2024, companies are capping inhaler-based therapies at USD 35 per month. This price-capping initiative enhances the treatment affordability and expands patient access to maintenance therapies.

Dosage Form Segment Analysis

In dosage forms, pressurized metered-dose inhalers (pMDIs) are expected to be the top sub-segment. They gain their superiority due to their convenience, consistency, and known familiarity with patients and physicians. Although Dry Powder Inhalers (DPIs) are favored, pMDIs continue to be vital among patients with weakened lung capacity who are unable to produce the force needed for DPIs. The U.S. Food and Drug Administration (FDA) proactively directs the development and shift of pMDIs to more eco-friendly propellants to ensure their sustained central position within treatment schemes and to maintain their commercial dominance.

Our in-depth analysis of the COPD therapeutics market includes the following segments: